1NAGASE H, VISSE R, MURPHY G, et al. Structure and function of matrix metalloproteinases and TIMPs [ J]. Cardiovasc Res, 2006, 69 (3): 562-573.
2WEBB C S, BONNEMA D D, AHMED S H, et al. Specific temporal profile of matrix metalloproteinase re- lease occurs in patients after myocardial infarction: rela- tion to left ventricular remodeling [ J ]. Circulation, 2006, 114 (10): 1020-1027.
3IKONOMIDIS J S, HENDRICK J W, PARKHURST A M, et al. Accelerated LV remodeling after myocardial infarction in TIMP-l-deficient mice : effects of exogenous MMP inhibition [ J ]. Am J Physiol Heart Circ Physiol, 2005, 288 (1) : HI49-58.
4MUKHERJEE R, SNIPES J M, SAUNDERS S M. et al. Discordant activation of gene promoters for mamtrix metalloproteinases and tissue inhibitors of the metallo- proteinases following myocardial infarction [ J ]. J Surg Res , 2012, 172, (1): 59-67.
5TRESCHER K, BERNECKER O, FELLNER B, et al. Inflammation and postinfarct remodeling: Overexpression of h(B prevents ventricular dilation via increasing TIMP levels [ J ]. Cardiovasc Res, 2006, 69 (3) : 746-754.
6YANG D, MA S, LI D, et al. Angiotensin II receptor blockade improves matrix metalloproteinases/tissue in- hibitor of matrix metalloproteinase-1 balance and restores fibronectin expression in rat infarcted myocardium [ J ]. Biochem Biophys Res Commun, 2009, 388 (3) : 606- 611.
7WANG Y, HU X, XIE X, et al. Effects of mesenchy- mal stem cells on matrix metalloproteinase synthesis in cardiac fibroblasts [ J ]. Exp Biol Med ( Maywood ) , 2011, 236 (10) : 1197-1204.
8LINDSAY M M, MAXWELL P, DUNN F G. TIMP-1 : a marker of left ventricular diastolic dysfunction and fibrosis in hypertension[ J ]. Hypertension, 2002, 40 (2) : 136- 141.
9LoPEZ B, GONZALEZ A, QUEREJETA R, et al. Alter- ations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive pa- tients with heart failure [ J ]. J Am Coil Cardiol, 2006, 48 ( 1 ) : 89-96.
10LIN J, DAVIS H B, DAI Q, et al. Effects of early and late chronic pressure overload on extracellular matrix re- modeling[J]. Hypertens Res, 2008, 31 (6): 1225-1231.
4Bai P,Mabley JG,LiaudetL,et al.Matrixmetalloproteinase activation is an early event in doxorubicin-inducedcardiotoxicity.Oncol Rep,2004,11 (2):505-508.
5Laura S,Abigail S,Robert E,et al.Membrane-type-1 matrix metalloproteinase transcription and translation in myocardial fibroblasts from patients with normal left ventricular function and from patients with cardiomyopathy.Physiol Cell Physiol,2007,293:C1362-C1373.
6Bai P,Mabley J G,Liaudet L,et al.Matrix metalloproteinase activation is an early event in doxorubicin-induced cardiotoxicity.Oncol Rep,2004,11:505-508.
7Jayasankar V,Woo YJ,Bish L T,et al.Inhibition of matrix metalloproteinase activity by TIMP-1 gene transfer effectively treat s ischemic cardiomyopathy.Circu-lation,2004,110:180-186.
8Chow AK,Cena J,Schulz R.Acute actions and novel targets of matrix metallo-proteinases in the heart and vascculatur.Br J Pharmacol,2007,152(2):189-205.
9Lodge PA, Herzum M, Olszewski J, et al. Coxsackievirus B - 3 myocarditis :Acute and chronic froms of the disease caused by different immunopathogenic mechanisms. Am J Pathology, 1987,128(3) :455.
10Li YY, McTieman CF, Feldman AM, et al. Interplay of natrix metalloproteinases,tissue inhibitors of metalloproteinases and their regulators in oardiac matrix remodeling. Cardiovasc Res ,2000,46(2): 214.
